Identification and characterization of protein sites

By replacing genetically-encoded amino acids with non-genetically-encoded amino acids to form covalent bonds with specificity-directing agents, the method enhances the evaluation of protein interactions and degradation, addressing the limitations of existing technologies in modulating proteins without 'druggable hotspots' and improving targeted protein degradation.

WO2024238349A1PCT designated stage expired Publication Date: 2024-11-21FRONTIER MEDICINES CORP

Patent Information

Application Number
PCT/US2024/028837
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-08
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current methods for evaluating specific regions and amino acid residues on proteins are limited, particularly for proteins without 'druggable hotspots' and in targeted protein degradation, due to challenges in modulating reactivity and accessibility, especially with methods like COFFEE which face issues with cell survival and contamination during electroporation.

Method used

A method involving replacing genetically-encoded amino acids with non-genetically-encoded amino acids, such as tetrazine or trans-cyclooctene moieties, to form covalent bonds with specificity-directing agents, allowing for precise evaluation of protein interactions and degradation processes.

Benefits of technology

Enables enhanced specificity and strength of protein interactions, facilitating targeted protein degradation and drug design by allowing for controlled modification and evaluation of protein sites without affecting other residues, thereby overcoming limitations of existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024028837_21112024_PF_FP_ABST
    Figure US2024028837_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Methods of determining the accessibility and / or functional utility of a specific amino acid in a protein are disclosed. The method involves replacing a specific genetically-encoded amino acid (GEAA) in the protein with a non-genetically-encoded amino acid (NGAA), where the NGAA reacts with a precursor to a specificity-directing agent. The precursor to a specificity-directing agent is a molecule which contains a functional group that reacts with the NGAA to form a covalent bond, and also a binding group that binds to a desired target. By replacing the GEAA with the NGAA, the accessibility and functional utility of that specific site in the protein can be assessed independently of other, potentially interfering, amino acids in the protein, and permits derivatization of the protein with the specificity- directing agent to bind to desired targets. Suitably accessible and / or reactive amino acids can be used, for example, as sites for PROTAC development.
Need to check novelty before this filing date? Find Prior Art

Description

IDENTIFICATION AND CHARACTERIZATION OF PROTEIN SITESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit of United States Provisional Patent Application No. 63 / 466,222, filed May 12, 2023, and of United States Provisional Patent Application No. 63 / 551,296, filed February 8, 2024. The entire contents of those patent applications are hereby incorporated by reference herein.FIELD OF THE INVENTION

[0002] The disclosure relates to methods of characterizing a specific genetically encoded amino acid in a protein, or the general region of the protein occupied by a specific genetically encoded amino acid, by replacing the genetically encoded amino acid with an amino acid which is not genetically encoded.BACKGROUND

[0003] Although numerous proteins have been identified as potential candidates for drug development, many of these proteins are difficult to modulate with small molecules. For example, proteins that do not possess obvious small molecule binding pockets — “druggable hotspots” — are often considered “undruggable.” This represents a major challenge in developing drugs that interact with such proteins.

[0004] Many proteins have amino acids that can be modified covalently, known as “hotspots.” One parameter that defines functional hotspots in the proteome is amino acid side-chain reactivity, which can vary by orders of magnitude for a given residue depending on the local protein microenvironment. Such hotspot amino acids, including cysteine, lysine, histidine, tyrosine, threonine, and serine, are highly enriched in functional residues that are involved in catalysis, protein-protein interactions, metal binding, post-translational modification, or allosteric regulation. These hotspot amino acids can be covalently modified using appropriate reagents.

[0005] Evaluating the reactivity and functional role of a specific amino acid residue in a protein can be difficult, particularly in a cellular environment. A given protein of interest may have multiple reactive amino acid residues of the same type of amino acid, such as multiple cysteine residues. If the protein is contacted with a drug candidate molecule that reacts with and covalently binds to cysteines, some cysteines in the protein may react to agreater extent than other cysteines. The difference in reactivity may or may not be due to the inherent reactivity of the specific residue. The difference in reactivity may be due to local protein microenvironment effects enhancing nucleophilicity of one specific cysteine versus other cysteine residues, in which case modification of the drug candidate molecule may redirect the molecule away from one cysteine site and towards another. The difference in reactivity may also be caused by steric inaccessibility of the less-reactive cysteines, in which case modification of the drug candidate molecule to re-direct the molecule may be difficult. In the cellular environment, other proteins with the same type of amino acid residue may compete for reaction with the drug candidate molecule, further complicating evaluation of the reactivity of a specific amino acid residue in the protein of interest. For example, if a second protein which is not of interest is present in a cell at a concentration several orders of magnitude higher than the first protein which is of interest, most of the cellular protein that reacts with the drug candidate molecule may be the second protein, even if the specific residue in the first protein is much more reactive than the same residue in the second protein.

[0006] Once the reactivity of amino acids in a protein is quantified, the functional utility of those amino acids needs to be determined in order to understand how to modify the protein in order to alter its activity in the desired manner. For example, modification of a particular reactive amino acid in a protein may prevent the protein from interacting with other proteins or substrates, while modification of other reactive amino acids in the same protein affect the function of the protein to a much lesser extent, or not at all. Evaluating the characteristics specific to each reactive residue site, independently of the other reactive residue sites, would be helpful in determining whether to concentrate efforts on a particular reactive residue for drug design.

[0007] Evaluation of specific residues in a protein can also be useful in targeted protein degradation (TPD). Targeted protein degradation relies on re-directing (“hijacking”) the protein degradation machinery of a cell against an undesired protein. An example of such redirection is the PROTAC® (PROteolysis TArgeting Chimera; PROTAC is a registered trademark of Arvinas Operations, Inc.) concept. A PROTAC is a bifunctional molecule with one group that binds to an undesired protein, and another group that binds to an E3 ligase. The PROTAC can bind to both the undesired protein and the E3 ligase, bringing the E3 ligase into proximity to the undesired protein. The E3 ligase can then label the undesired protein with ubiquitin, which tags the undesired protein for destruction by the proteasome.

[0008] A given PROTAC will bind to a specific region of an E3 ligase, and also to a specific region of the undesired protein. However, regions on an E3 ligase or on an undesiredprotein may differ in their suitability for PROTAC development. For example, a PROTAC that binds to the E3 ligase in a region that is too close to the active site of the E3 ligase may hinder the E3 ligase from labeling the undesired protein with ubiquitin, decreasing or even eliminating any degradation of the undesired protein. Similarly, certain regions of the undesired protein may be optimal for ubiquitination; if those regions are blocked by the binding of the PROTAC, degradation of the undesired protein will be hindered.

[0009] A method for evaluating the ability of modified recombinant E3 ligases to degrade new targets has been developed, called “covalent functionalization followed by E3 electroporation” or COFFEE (Pinch et al., Cell Chem Biol. 2022 Jan 20;29(l):57-66.e6). This method relies on derivatization of an isolated E3 ligase complex to alter its substrate specificity, followed by electroporation of the E3 ligase into cells. As electroporation utilizes electric fields to open breaches in the cell membrane, it has several disadvantages. Cell necrosis can be significant if the cell cannot repair the damage to the cell membrane inherent to electroporation, and often large quantities of cells must be used to ensure that sufficient cells survive the procedure. Even when the cell survives, contaminating molecules may have also entered the cell during electroporation, with the potential to affect and skew the results of the study. Additionally, the COFFEE method relies on derivatization of cysteine residues in the protein under investigation. This limits the positions that can be derivatized, and complicates studies of proteins with multiple cysteine residues.

[0010] Accordingly, new methods of evaluation of specific regions, sites, and amino acid residues on proteins would be of significant value in both traditional medicinal chemistry efforts, and in non-traditional efforts such as targeted protein degradation.SUMMARY OF THE INVENTION

[0011] The current disclosure provides methods and techniques for evaluating proteins, by examining the effect of derivatizing specific sites on a protein on the interactions of that protein with other proteins, protein aggregates, or protein complexes.

[0012] In one embodiment, provided herein is method of evaluating the interaction of a target with a derivatized protein, comprising replacing a genetically-encoded amino acid (GEAA) of a first protein with a non-genetically-encoded amino acid (NGAA); reacting the NGAA with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the first protein to the specificity-directing agent to form the derivatized protein; and evaluating the interaction of the derivatized protein with the target. In embodiments, the derivatized protein binds to the target. In embodiments, the first proteindoes not bind to the target. In embodiments, the derivatized protein binds to the target at least 10 times more strongly than the first protein binds to the target.

[0013] The target can comprise a second protein. The target can comprise a protein complex. The target can comprise a protein aggregate.

[0014] The non-genetically-encoded amino acid can comprise a tetrazine moiety. The non- genetically-encoded amino acid can comprise (S)-2-amino-3-(3-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6- methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid. (S)-2-amino-3-(4-(6-ethyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid.

[0015] The non-genetically-encoded amino acid can comprise a trans-cyclooctene moiety

[0016] The precursor to a specificity-directing agent can comprises a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

[0017] Evaluating the interaction of the target in the cell or cell lysate can comprise comparing an amount of the target in the cell or cell lysate with the derivatized protein with an amount of the target in a cell or cell lysate without the derivatized protein. Evaluating the interaction of the target in the cell or cell lysate can comprises comparing an amount of the target in the cell or cell lysate where the precursor to a specificity-directing agent was added with an amount of the target in a second cell or second cell lysate where the precursor to a specificity-directing agent was not added. Evaluating the interaction of the target in the cell or cell lysate can comprise comparing an amount of the target in the cell or cell lysate with an amount of the target in a second cell or second cell lysate lacking the first protein. Evaluating the interaction of the target by the derivatized protein can comprises comparing a level of activity of the target in the cell or cell lysate with the target with a level of activity of the target in a cell or cell lysate without the target.

[0018] In embodiments, the first protein is a protein that induces degradation of the target. The first protein can be an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein.

[0019] The target can be a protein susceptible to aggregation. The target can be huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prionprotein). The target can be Huntingtin aggregate, beta- amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

[0020] The first protein can be huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non-scrapie isoform of the prion protein).

[0021] The target can be a protein that induces degradation of the derivatized protein. The target can be an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein. The target can be Von Hippel-Lindau (VHL) E3 ligase or Cereblon.

[0022] In a further embodiment, provided is a method of evaluating the degradation of a target by an E3 ligase in a cell or cell lysate, comprising replacing an amino acid of a target protein with a non-genetically-encoded amino acid (NGAA); reacting the non-genetically- encoded amino acid with a precursor to an E3-ligase-binding agent, wherein the reacting results in covalent binding of the target protein to the E3-ligase binding agent to form an E3- ligase-binding target protein; and evaluating the degradation of the target in the cell or cell lysate.

[0023] The amino acid of the target protein can be a cysteine, lysine, serine, threonine, histidine, tyrosine, glutamic acid, or aspartic acid residue. The E3-ligase-binding target protein can bind to an E3 ligase in the cell or cell lysate. The target can comprise the target protein. The target can comprise a protein complex comprising the target protein. The target can comprise an aggregate of the target protein.

[0024] The non-genetically-encoded amino acid can comprise a tetrazine moiety. The non- genetically-encoded amino acid can comprise (S)-2-amino-3-(3-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6- methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid.

[0025] The non-genetically-encoded amino acid can comprises a trans-cyclooctene moiety.

[0026] The precursor to an E3 -ligase-binding agent can comprise a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to an E3 ligase.

[0027] The target can be a protein susceptible to aggregation. The target can be Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein). The target protein can be huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non-scrapie isoform of the prion protein).

[0028] Evaluating the degradation of the target in the cell or cell lysate can comprises: comparing an amount of the target in the cell or cell lysate with the E3-ligase-binding target protein with an amount of the target in a cell or cell lysate without the E3-ligase-binding target protein; or comparing an amount of the target in the cell or cell lysate where the E3-ligase-binding agent was added with an amount of the target in a second cell or second cell lysate where the E3- ligase-binding agent was not added; or comparing an amount of the target in the cell or cell lysate with an amount of the target in a second cell or second cell lysate lacking the E3 ligase; or comparing a level of activity of the target in the cell or cell lysate with the E3-ligase-binding target protein with a level of activity of the target in a cell or cell lysate without the E3-ligase- binding target protein.

[0029] The E3 ligase can be Von Hippel-Lindau (VHL) E3 ligase. The E3 ligase can be Cereblon.

[0030] In a further embodiment, provided is a method of evaluating the degradation of a target in a cell or cell lysate by a targeting degrader protein, comprising replacing a genetically encoded amino acid of a degrader protein with a non-genetically-encoded amino acid; reacting the non-genetically-encoded amino acid with a precursor to a specificitydirecting agent, wherein the reacting results in covalent binding of the degrader protein to the precursor to a specificity-directing agent to form a targeting degrader protein; and evaluating the degradation of the target by the targeting degrader protein.

[0031] The degrader protein can be an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein. The targeting degrader protein can bind to the target.

[0032] In embodiments, the degrader protein does not bind to the target. In embodiments, the targeting degrader protein binds to the target at least 10 times more strongly than the degrader protein binds to the target.

[0033] In embodiments, the target is a protein. In embodiments, the target is a protein aggregate. In embodiments, the target comprises a protein complex comprising the target protein.

[0034] The non-genetically-encoded amino acid can comprise a tetrazine moiety. The non- genetically-encoded amino acid can comprise (S)-2-amino-3-(3-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6- methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid.

[0035] The non-genetically-encoded amino acid can comprise a trans-cyclooctene moiety.

[0036] The precursor to a specificity-directing agent can comprise a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

[0037] The target can be a protein susceptible to aggregation. The target can be Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein). The target can be huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

[0038] Evaluating the degradation of the target by the targeting degrader protein can comprise: comparing an amount of the target in the cell or cell lysate with the targeting degrader protein with an amount of the target in a cell or cell lysate without the targeting degrader protein; or comparing a level of activity of the target in the cell or cell lysate with the targeting degrader protein with a level of activity of the target in a cell or cell lysate without the targeting degrader protein.

[0039] In a further embodiment, provided is a method of evaluating the degradation of a target by a targeting E3 ligase in a cell or cell lysate, comprising replacing a genetically encoded amino acid of a selected E3 ligase with a non-genetically-encoded amino acid; reacting the non-genetically-encoded amino acid with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the selected E3 ligase to the precursor to a specificity-directing agent to form a targeting E3 ligase; and evaluating the degradation of the target by the targeting E3 ligase.

[0040] In embodiments, the targeting E3 ligase binds to the target. In embodiments, the selected E3 ligase does not bind to the target. In embodiments, the targeting E3 ligase binds to the target at least 10 times more strongly than the selected E3 ligase binds to the target.

[0041] The target can be a protein. In embodiments, the target can be a protein aggregate. In embodiments, the target can comprise a protein complex comprising the target protein.

[0042] The non-genetically-encoded amino acid can comprise a tetrazine moiety. The non- genetically-encoded amino acid can comprise (S)-2-amino-3-(3-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6- methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid.

[0043] The non-genetically-encoded amino acid can comprise a trans-cyclooctene moiety.

[0044] The precursor to a specificity-directing agent can comprise a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

[0045] The target can be a protein susceptible to aggregation. The target can be Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein). The target can be huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

[0046] Evaluating the degradation of the target by the targeting E3 ligase can comprise: comparing an amount of the target in the cell or cell lysate with the targeting E3 ligase with an amount of the target in a cell or cell lysate without the targeting E3 ligase; or comparing a level of activity of the target in the cell or cell lysate with the targeting E3 ligase with a level of activity of the target in a cell or cell lysate without the targeting E3 ligase.

[0047] In a further embodiment, provided is a method of characterizing a candidate site in a candidate protein for PROTAC development, comprising evaluating the interaction of a target with a derivatized candidate protein wherein the candidate protein is derivatized by replacing a genetically-encoded amino acid (GEAA) at the candidate site in the candidate protein with a non-genetically-encoded amino acid (NGAA), and reacting the NGAA with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding ofthe candidate protein to the specificity-directing agent to form the derivatized candidate protein; and wherein the evaluation of the interaction of the target with the derivatized candidate protein comprises one or more of: comparing binding of the derivatized candidate protein to the target versus binding of the candidate protein to the target, comparing the amount of the target in the presence of the derivatized candidate protein with the amount of the target in the absence of the derivatized candidate protein, comparing an amount of the target in a first cell or cell lysate with the derivatized candidate protein versus an amount of the target in a second cell or cell lysate without the derivatized candidate protein, comparing a level of activity of the target in a first cell or cell lysate with the derivatized candidate protein versus a level of activity of the target in a second cell or cell lysate without the derivatized candidate protein, comparing stability of the target with the derivatized candidate protein versus stability of the target with the candidate protein, comparing a level of phosphorylation of the target in a first cell or cell lysate with the derivatized candidate protein versus the level of phosphorylation of the target in a second cell or cell lysate without the derivatized candidate protein, or comparing a level of dephosphorylation of the target in a first cell or cell lysate with the derivatized candidate protein versus the level of dephosphorylation of the target in a second cell or cell lysate without the derivatized candidate protein.

[0048] The evaluating can comprise comparing the amount of the target in the presence of the derivatized candidate protein with the amount of the target in the absence of the derivatized candidate protein.

[0049] The features of any of the embodiments recited above and herein are combinable with any of the other embodiments recited above and herein where appropriate and practical.BRIEF DESCRIPTION OF THE DRAWINGS

[0050] FIG. 1 shows the steps involved in modifying a protein in order to enable the protein to bind to a specific target.

[0051] FIG. 2 shows the steps involved in modifying an E3 ligase protein in order to enable the E3 ligase protein to bind to a specific target.

[0052] FIG. 3 shows the steps involved in modifying a target protein in order to enable the target protein to bind to an E3 ligase protein.

[0053] FIG. 4 shows the degradation of green fluorescent protein (GFP) in cells where the GFP has been modified with a precursor to an E3-ligase-binding agent.DETAILED DESCRIPTION

[0054] Disclosed herein are methods of evaluating the functional role and functional utility of specific amino acids at specific locations in a protein. In one embodiment, the methods can be used to modify an E3 ligase at a specific amino acid residue, in order to direct the E3 ligase to bind to a specific target, resulting in ubiquitination and subsequent degradation of the target. In a further embodiment, the methods can be used to modify a target protein at a specific amino acid residue, in order to direct the target to bind to an E3 ligase, also resulting in ubiquitination and subsequent degradation of the target. These methods enable recruitment of a novel substrate to an E3 ligase (that is, directing an E3 ligase against a different target), or recruiting an E3 ligase to a novel substrate (that is, endowing a target molecule with the ability to recruit an E3 ligase). Evaluation of the levels of target protein in cells after such modifications provides information about the accessibility and functional utility of the specific amino acid residue where the modification was made, as well as about the local protein microenvironment of the specific amino acid residue. This information can direct efforts in drug design and other uses of the protein.I. Definitions

[0055] “Genetically encoded amino acid” or “GEAA” refers to a naturally-occurring amino acid that is encoded by naturally-occurring eukaryotic nuclear DNA and which are incorporated into proteins by ribosomal synthesis. The amino acids encoded by eukaryotic nuclear DNA are L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.

[0056] ‘ ‘Non-genetically encoded amino acid” or “NGAA” refers to an amino acid, whether naturally occurring or synthetic, that is not encoded by naturally-occurring eukaryotic nuclear DNA.

[0057] A “protein complex” is an association of two or more proteins. The complex may be formed by multiple units of the same protein. The complex may be formed by one or more units of the same protein associated with one or more units of one or more different proteins. The association can be non-covalent association, or the association can be covalent bonding. A protein complex may also comprise other cellular elements, such as nucleic acids, lipids, polysaccharides, and other biological molecules or biological macromolecules.

[0058] A “protein aggregate” is an aggregation of two or more misfolded protein monomers.Derivatizing a Protein to Bind to a Specific Target

[0059] In one embodiment, the method comprises derivatizing a protein in order to enable the protein to bind to a specific target. This method comprises replacing a genetically- encoded amino acid (GEAA) at a specified location in a protein with a non-genetically encoded amino acid (NGAA) at that location in the protein. The non-genetically encoded amino acid selectively reacts with a functional group to form a covalent bond, where the functional group does not react with genetically-encoded amino acids to any significant extent. In this manner, chemistry can be carried out at the location of the genetically-encoded amino acid — which has been replaced with the non-genetically encoded amino acid — without affecting other locations with the same type of amino acids. For example, if a protein has cysteine residues at positions 100, 137, and 214 of its sequence, the cysteine at position 137 can be replaced with a non-genetically encoded amino acid. That NGAA can then be derivatized by reaction with a functional group that reacts selectively with the NGAA; that is, the functional group reacts with the NGAA, but the functional group does not react to any significant extent with genetically-encoded amino acids. The activity of the derivatized protein can then be examined.

[0060] The functional group that the NGAA selectively reacts with can be part of a larger molecule. The larger molecule can also have a moiety which specifically binds to a particular target. This larger molecule, which has a functional group for reaction with the NGAA to form a covalent bond and a binding group which specifically binds to a particular target, is a “precursor to a specificity-directing agent.” Once the precursor to a specificity-directing agent reacts covalently with the NGAA of the protein, it forms a derivatized protein, where the remainder of the precursor becomes a “specificity-directing agent,” enabling the derivatized protein to form a complex with the particular target which is bound by the binding group. The effect of the derivatized protein on the particular target can then beexamined. For example, if the derivatized protein is an E3 ligase and the target is a misfolded protein which causes pathology, formation of the complex of the E3 ligase and the target can result in ubiquitination and subsequent degradation of the target.

[0061] Addition of the precursor to a specificity-directing agent to the protein, to form the protein derivatized with a specificity-directing agent, permits targeting the derivatized protein against a new target, to which the original protein (prior to replacement of a genetically- encoded amino acid with a non-genetically encoded amino acid and derivatization with the specificity-directing agent) did not bind. Addition of the precursor to a specificity-directing agent to the protein, to form the protein derivatized with a specificity-directing agent, permits targeting the derivatized protein against a new target, to which the original protein (prior to replacement of a genetically-encoded amino acid with a non-genetically encoded amino acid and derivatization with the specificity-directing agent) bound only non- specifically or did not bind at all.

[0062] Addition of the precursor to a specificity-directing agent to the protein, to form the protein derivatized with a specificity-directing agent, permits targeting the derivatized protein against a new target, to which the original protein (prior to replacement of a genetically- encoded amino acid with a non-genetically encoded amino acid acid and derivatization with the specificity-directing agent) to which the original protein bound more weakly than the derivatized protein, that is, to which the derivatized protein binds more strongly than the original protein. The derivatized protein may bind about two times more strongly, about five times more strongly, about ten times more strongly, about 50 times more strongly, about 100 times more strongly, about 500 times more strongly, about 1000 times more strongly to the target than the original protein, about 10,000 times more strongly to the target than the original protein, about 100,000 times more strongly to the target than the original protein, or about 1,000,000 times more strongly to the target than the original protein. The derivatized protein may bind at least about two times more strongly, at least about five times more strongly, at least about ten times more strongly, at least about 50 times more strongly, at least about 100 times more strongly, at least about 500 times more strongly, at least about 1000 times more strongly to the target than the original protein, at least about 10,000 times more strongly to the target than the original protein, at least about 100,000 times more strongly to the target than the original protein, or at least about 1,000,000 times more strongly to the target than the original protein. The derivatized protein may bind about two to about 100 times more strongly, about five to about 100 times more strongly, about ten to 100 times more strongly, about 50 to about 100 times more strongly, about 100 to about 1000 timesmore strongly, about 500 to about 1000 times more strongly, about 1000 to about 10,000 times more strongly to the target than the original protein, about 10,000 to about 100,000 times more strongly to the target than the original protein, or about 100,000 to about 1,000,000 times more strongly to the target than the original protein. The derivatized protein may bind to the target whereas the original protein did not bind to the target. The derivatized protein may bind specifically to the target whereas the original protein bound only non- specifically to the target.

[0063] The activity of the derivatized protein depends on the ability of the precursor to a specificity-directing agent to react specifically with the non-genetically encoded amino acid. Therefore, the NGAA should react readily and specifically under cellular conditions (that is, in a cell or cell lysate) with the portion of the specificity-directing agent described as having the functional group that the NGAA selectively reacts with. One example of such an NGAA and functional group is the tetrazine-trans-cyclooctene pair. Other examples of NGAAs and functional groups are discussed herein in various sections, including “Non-Genetically- Encoded Amino Acids to use as Replacements.”

[0064] This general concept is illustrated in FIG. 1. A specific genetically-encoded amino acid (GEAA) in a particular protein is chosen for evaluation, at step (i) of FIG. 1. The particular protein is representedstep (ii) of FIG. 1, the genetically- encoded amino acid (GEAA) is replaced by a non-genetically-encoded amino acid (NGAA), for example, by amber codon suppression, resulting in a modified protein.

[0065] The modified protein is then contacted with the precursor to the specificity-directing agent, which has a functional group for reaction with the NGAA to form a covalent bond and a binding group which specifically binds to a particular target. The precursor reacts with the NGAA of the protein to form a protein with a covalently-attached specificity-directing agent at step (iii) of FIG. 1.

[0066] Contacting the target, represented byFIG. 1, to which the binding group of the specificity-directing agent is directed, with the protein with the covalently-attached specificity-directing agent, then can result in a complex comprising the target and the protein with the covalently-attached specificity-directing agent. This is shown at step (iv) of FIG. 1.

[0067] A specific application of this method is shown in FIG. 2. In FIG. 2, the particular protein is an E3 ligase, representedspecific genetically-encoded amino acid (GEAA) in the E3 ligase is chosen for evaluation at step (i) of FIG. 2. The GEAA is replaced by a non-genetically-encoded amino acid (NGAA) at step (ii) of FIG. 2. Reacting the NGAA with a precursor to a specificity-directing agent results in covalent binding of the E3 ligase to the specificity-directing agent to form a targeting E3 ligase at step (iii) of FIG. 2. Finally, contacting the targeting E3 ligase with the target ,?results in a complex of the target and the targeting E3 ligase, as shown in step (iv) of FIG. 2. E3 ligases function to tag undesired proteins in cells with ubiquitin, which signals to the cell that the undesired protein should be degraded in the proteasome.

[0068] The level of target protein in a cell in which the targeting E3 ligase has been formed by the methods described herein can be compared to the level of target protein in a control cell, where the targeting E3 ligase has not been formed. This in turn provides important information about the specific genetically-encoded amino acid (GEAA) which was replaced by the non-genetically-encoded amino acid (NGAA) in the E3 ligase, and about the local protein microenvironment of that GEAA. If the level of target protein in a cell in which the targeting E3 ligase has been formed by the methods described herein is significantly lower than the level in the control cell, this indicates that (1) the region around the GEAA chosen for study is accessible to agents which can react covalently at that location, such as the specificity-directing agent; and (2) that, after reaction of the specificity-directing agent with the targeting E3 ligase, the E3 ligase retains its ability to tag the target protein for degradation in the proteasome.

[0069] FIG. 3 shows a similar method as described in FIG. 2, but with substitution of the specific genetically-encoded amino acid (GEAA) by the non-genetically-encoded amino acid (NGAA) in the target of the E3 ligase, instead of in the E3 ligase itself. A specific genetically-encoded amino acid (GEAA) in the target protein,, is chosen for evaluation at step (i) of FIG. 3. The GEAA is replaced by a non-genetically-encoded amino acid (NGAA) at step (ii) of FIG. 3. Reacting the NGAA with a precursor to a E3-ligase binding agent results in covalent binding of the target protein to the specificity-directingagent to form an E3 -ligase-binding target protein at step (iii) of FIG. 3. Finally, contacting the E3-ligase-binding target protein with the E3 ligase,, results in a complex of theE3 -ligase-binding target protein and the E3 ligase, as shown in step (iv) of FIG. 3. If the level of target protein in a cell in which the E3 -ligase-binding target protein has been formed by the methods described herein is significantly lower than the level in the control cell, this indicates that (1) the region around the GEAA chosen for study is accessible to agents which can react covalently at that location, such as the specificity-directing agent; and (2) that, after reaction of the specificity-directing agent with the target protein, E3-ligase-binding target protein can still be tagged by the E3 ligase for degradation in the proteasome.

[0070] Examples of E3 ligases that can be used in the methods described above include, but are not limited to, von Hippel-Lindau protein (VHL), also known as von Hippel-Lindau (VHL) E3 ligase, and Cereblon.

[0071] The methods above exemplify use of an E3 ligase to bind to the target, in order to degrade the target in the proteasome. The methods can be practiced using an autophagydirecting protein instead of the E3 ligase. Forming an [autophagy-directing protein]- [specificity-directing agent] -[target] complex will direct the target into the autophagy pathway, resulting in degradation of the target in the autophagosome. Examples of autophagy-directing proteins include, but are not limited to, LC3, p62, NBR1, NDP52, Optineurin, NUFIP1, WDFY3, RETREG1, Nix, TOLLIP, TAX1BP1, TEX264, BNIP3, FYCO1, NCOA4, PRKAR1A, RTN3, STBD1, and YIPF4.Use of Information from Evaluation of Protein-Protein Interactions

[0072] The methods disclosed herein for evaluation of protein-protein interactions yield valuable information about the structure and function of the proteins involved in the interaction. In particular, the methods disclosed herein will permit screening of specific candidate sites in candidate proteins, to determine the suitability of the candidate sites for various uses in medicinal chemistry, drug design, and other applications, where the candidate sites are involved directly or indirectly in protein-protein interactions.

[0073] One such application in medicinal chemistry is in design of proteolysis-targeting chimeras, or PROTACs. PROTACs have become an increasingly important area of researchin the pharmaceutical industry. A PROTAC is a bifunctional molecule with one group that binds to an undesired protein, and another group that binds to an E3 ligase. The PROTAC can bind to both the undesired protein and the E3 ligase, bringing the E3 ligase into proximity to the undesired protein. The E3 ligase can then label the undesired protein with ubiquitin, which tags the undesired protein for destruction by the proteasome.

[0074] However, if a PROTAC binds to the E3 ligase in a region that is too close to the active site of the E3 ligase, it may hinder the E3 ligase from labeling the undesired protein with ubiquitin, and degradation of the undesired protein will be reduced or completely blocked. Alternatively, if a PROTAC binds to the E3 ligase in a region that is too distant from the active site of the E3 ligase, the E3 ligase may be unable to label the undesired protein with ubiquitin, and degradation of the undesired protein will be reduced or completely blocked. If regions of the undesired protein required for ubiquitination are blocked by the binding of the PROTAC, again, degradation of the undesired protein will be reduced or completely blocked. Several E3 ligases function in the context of a larger complex, and if PROTAC binding disrupts the complex, again, the E3 ligase will not be able to label the undesired protein with ubiquitin, preventing degradation of the undesired protein.

[0075] The methods disclosed herein can be used to characterize a candidate site on a candidate protein. Evaluation of the candidate site by the methods disclosed herein can provide information as to (1) whether the candidate site is amenable to derivatization by small molecules; and (2) whether, once derivatized at the candidate site, the candidate protein retains sufficient function for its intended purpose, and can interact with other proteins appropriately. For example, when the candidate protein is an E3 ligase that is the subject of PROTAC development, there may be multiple candidate sites on the E3 ligase which can be selected for PROTAC development. Evaluation of each of the candidate sites by the methods disclosed herein can inform the medicinal chemist about the likelihood of success with a PROTAC designed to interact specifically with a single candidate site on the E3 ligase, and indicate whether to proceed with a PROTAC for that candidate site. The information thus derived can save significant amounts of time, effort, and resources by identifying suitable and unsuitable candidate sites, allowing the PROTAC design work to be directed to the most suitable sites on the E3 ligase.Selection of Genetically-Encoded Amino Acids for Replacement

[0076] Selection of the genetically-encoded amino acid (GEAA) to be replaced by a non- genetically-encoded amino acid (NGAA) may be based on any one or more of numerouscriteria, including, but not limited to, the following characteristics. The GEAA may be known to be susceptible, or believed to be susceptible, to covalent reaction with an electrophilic ligand; for example, the GEAA may be a cysteine residue. For replacement of a GEAA with an NGAA in an E3 protein, the GEAA (such as cysteine) may be near the substrate binding domain (when the region of the binding domain is known). The GEAA may be in the active site of an enzyme. The GEAA may be at a protein-protein interaction interface. The GEAA may have a posttranslational modification of interest. The GEAA may be highly conserved across a variety of species, indicating that it is important to the function of the protein. The GEAA may be identified during chemoproteomic screens or other evaluations as being of particular interest.Non-Genetically-Encoded Amino Acids to use as Replacements

[0077] Various non-genetically-encoded amino acids (NGAAs) can be selected to use as replacements for genetically-encoded amino acids (GEAAs) for use in the methods described herein. An NGAA chosen for use should be able to be substituted into a protein in place of the selected GEAA in the protein, whether by amber codon suppression or by other methods. The chosen NGAA should be relatively inert to reaction with other molecules in the cell, cell lysate, or other composition in which it is produced. The chosen NGAA should be able to react specifically and in good yield with the portion of the precursor to the specificitydirecting agent containing the functional group for reaction with the NGAA, to form a covalent bond between the NGAA and the specificity-directing agent.

[0078] Examples of such NGAAs are the tetrazine-substituted phenylalanines described in Jang et al., J. Am. Chem. Soc. 2020 April 22; 142(16): 7245-7249, where R1is selected from methyl, ethyl, isopropyl, or n-butyl:which include (S)-2-amino-3-(3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6- isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, and (S)-2-amino-3-(4-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid. Additional examples of such NGAAs are (S)-2-amino-3-(4-(6- ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, and (S)-2-amino-3-(4-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid. These tetrazine-substituted amino acids react specifically, under mild conditions (such as conditions found in cells or cell lysates) and in good yields with trans-cyclooctene,to form a covalent bond. Trans-cyclooctene moieties can be incorporated into larger molecules in order to attach other functionalities to the tetrazine-substituted amino acid, such as a binding group which specifically binds to a particular target.

[0079] Additional tetrazine-bearing amino acids are disclosed in Jana et al. (J. Am. Chem. Soc. 2023, 145, 14608-14620):, ch are, respectively, (S)-2-amino-3-(6-methyl-l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-phenyl- 1,2,4, 5-tetrazin-3- yl)propanoic acid, and (S)-2-amino-3-(6-(pyridin-2-yl)-l,2,4,5-tetrazin-3-yl)propanoic acid.These amino acids can be used in the methods disclosed herein.

[0080] The trans-cyclooctene / tetrazine chemistry above can also be employed by using an NGAA with a trans-cyclooctene side chain. Such an amino acid will react with a precursor to the specificity-directing agent containing a tetrazine functional group. Chemistry suitable for such amino acids is described in Selvaraj and Fox, Curr. Opin. Chem. Biol. 2013, 17(5):753- 60 (see also Liu et al., J. Am. Chem. Soc. 2012, 134, 10317-10320). Trans-cyclooctene amino acids can also react with a precursor to the specificity-directing agent containing an azide functional group.

[0081] Other functional groups suitable for use in NGAAs include alkynes, which are reactive with azides; and azides, which are reactive with alkynes or with trans-cyclooctyne.Targets

[0082] Virtually any molecule, complex, or aggregate present in a cell or cell lysate can be selected as the target. The target can be a protein, protein complex, or protein aggregate. In particular, the target can be a protein, protein complex, or protein aggregate associated with a disease. For example, the target can be a protein susceptible to aggregation. The target can be huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion. The target can be a disease-associated aggregate, such as Huntingtin aggregate, betaamyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

[0083] Alternatively, the target can be a protein that induces degradation of, or participates in the degradation of, a cellular component. The cellular component can be a protein, a protein complex, or a protein aggregate. The cellular component can be derivatized to bind to and interact with the protein that induces degradation of or that participates in the degradation of the cellular component. Proteins that induce degradation of a cellular component or that participate in the degradation of a cellular component include E3 ligases, E2 ligases, El ligases, and autophagy-directing proteins. A protein that induces degradation of a cellular component or that participates in the degradation of a cellular component are referred to as a “degrader protein.” Autophagy-directing proteins are proteins that, when associated with a cellular component, direct the cellular component into the autophagy pathway, leading to degradation of the cellular component. Examples of E3 ligases include, but are not limited to, von Hippel-Lindau protein (VHL), also known as von Hippel-Lindau (VHL) E3 ligase, and Cereblon. Examples of autophagy-directing proteins include, but are not limited to, LC3, p62, NBR1, NDP52, Optineurin, NUFIP1, WDFY3, RETREG1, Nix, TOLLIP, and TAX1BP1. Additional examples of autophagy-directing proteins include, but are not limited to, TEX264, BNIP3, FYCO1, NCOA4, PRKAR1A, RTN3, STBD1, and YIPF4.Exemplary Embodiments

[0084] The invention is further described by the following exemplary embodiments. The features of each of the embodiments are combinable with any of the other embodiments where appropriate and practical.

[0085] Embodiment 1. A method of evaluating the interaction of a target with a derivatized protein, comprising: replacing a genetically-encoded amino acid (GEAA) of a first protein with a non-genetically- encoded amino acid (NG A A); reacting the NGAA with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the first protein to the specificity-directing agent to form the derivatized protein; and

[0086] evaluating the interaction of the derivatized protein with the target.

[0087] Embodiment 2. The method of embodiment 1, wherein the derivatized protein binds to the target.

[0088] Embodiment 3. The method of embodiment 1 or embodiment 2, wherein the first protein does not bind to the target.

[0089] Embodiment 4. The method of embodiment 1 or embodiment 2, wherein the derivatized protein binds to the target at least 10 times more strongly than the first protein binds to the target.

[0090] Embodiment 5. The method of any one of embodiments 1-4, wherein the target comprises a second protein.

[0091] Embodiment 6. The method of any one of embodiments 1-4, wherein the target comprises a protein complex.

[0092] Embodiment 7. The method of any one of embodiments 1-4, wherein the target comprises a protein aggregate.

[0093] Embodiment 8. The method of any one of embodiments 1-7, wherein the non- genetically-encoded amino acid comprises a tetrazine moiety.

[0094] Embodiment 9. The method of embodiment 8, wherein the non-genetically-encoded amino acid is (S)-2-amino-3-(3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6- isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid.

[0095] Embodiment 10. The method of any one of embodiments 1-7, wherein the non- genetically-encoded amino acid comprises a trans-cyclooctene moiety

[0096] Embodiment 11. The method of any one of embodiments 1-10, wherein the precursor to a specificity-directing agent comprises:a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

[0097] Embodiment 12. The method of any one of embodiments 1-11, wherein evaluating the interaction of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with the derivatized protein with an amount of the target in a cell or cell lysate without the derivatized protein.

[0098] Embodiment 13. The method of any one of embodiments 1-11, wherein evaluating the interaction of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate where the precursor to a specificity-directing agent was added with an amount of the target in a second cell or second cell lysate where the precursor to a specificity-directing agent was not added.

[0099] Embodiment 14. The method of any one of embodiments 1-11, wherein evaluating the interaction of the target in the cell or cell lysate comprises:

[0100] comparing an amount of the target in the cell or cell lysate with an amount of the target in a second cell or second cell lysate lacking the first protein.

[0101] Embodiment 15. The method of any one of embodiments 1-11, wherein evaluating the interaction of the target by the derivatized protein comprises:

[0102] comparing a level of activity of the target in the cell or cell lysate with the target with a level of activity of the target in a cell or cell lysate without the target.

[0103] Embodiment 16. The method of any one of embodiments 1-15, wherein the first protein is a protein that induces degradation of the target.

[0104] Embodiment 17. The method of embodiment 16, wherein the first protein is an E3 ligase, an E2 ligase, an El ligase, or an autophagy -directing protein.

[0105] Embodiment 18. The method of any one of embodiments 1-17, wherein the target is a protein susceptible to aggregation.

[0106] Embodiment 19. The method of any one of embodiments 1-17, wherein the target is Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

[0107] Embodiment 20. The method of any one of embodiments 1-15, wherein the first protein is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

[0108] Embodiment 21. The method of any one of embodiments 1-15 or 20, wherein the target is a protein that induces degradation of the derivatized protein.

[0109] Embodiment 22. The method of embodiment 21, wherein the target is an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein.

[0110] Embodiment 23. The method of embodiment 21, wherein the target is Von Hippel- Lindau (VHL) E3 ligase or Cereblon.

[0111] Embodiment 24. A method of evaluating the degradation of a target by an E3 ligase in a cell or cell lysate, comprising: replacing an amino acid of a target protein with a non-genetically-encoded amino acid (NGAA); reacting the non-genetically-encoded amino acid with a precursor to an E3-ligase-binding agent, wherein the reacting results in covalent binding of the target protein to the E3-ligase binding agent to form an E3 -ligase-binding target protein; and

[0112] evaluating the degradation of the target in the cell or cell lysate.

[0113] Embodiment 25. The method of embodiment 24, wherein the amino acid of the target protein is a cysteine, lysine, serine, threonine, histidine, tyrosine, glutamic acid, or aspartic acid residue.

[0114] Embodiment 26. The method of embodiment 24 or embodiment 25, wherein the E3-ligase-binding target protein binds to an E3 ligase in the cell or cell lysate.

[0115] Embodiment 27. The method of any one of embodiments 24-26, wherein the target comprises the target protein.

[0116] Embodiment 28. The method of any one of embodiments 24-26, wherein the target comprises a protein complex comprising the target protein.

[0117] Embodiment 29. The method of any one of embodiments 24-26, wherein the target comprises an aggregate of the target protein.

[0118] Embodiment 30. The method of any one of embodiments 24-29, wherein the non- genetically-encoded amino acid comprises a tetrazine moiety.

[0119] Embodiment 31. The method of embodiment 30, wherein the non-genetically- encoded amino acid is (S)-2-amino-3-(3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3- (3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl- l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-methyl-l,2,4,5-tetrazin- 3-yl)phenyl)propanoic acid.

[0120] Embodiment 32. The method of any one of embodiments 24-29, wherein the non- genetically-encoded amino acid comprises a trans-cyclooctene moiety.

[0121] Embodiment 33. The method of any one of embodiments 24-32, wherein the precursor to an E3-ligase-binding agent comprises: a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to an E3 ligase.

[0122] Embodiment 34. The method of any one of embodiments 24-33, wherein the target is a protein susceptible to aggregation.

[0123] Embodiment 35. The method of any one of embodiments 24-33, wherein the target is Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

[0124] Embodiment 36. The method of any one of embodiments 24-33, wherein the target protein is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

[0125] Embodiment 37. The method of any one of embodiments 24-36, wherein evaluating the degradation of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with the E3-ligase-binding target protein with an amount of the target in a cell or cell lysate without the E3-ligase-binding target protein.

[0126] Embodiment 38. The method of any one of embodiments 24-36, wherein evaluating the degradation of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate where the E3-ligase-binding agent was added with an amount of the target in a second cell or second cell lysate where the E3- ligase-binding agent was not added.

[0127] Embodiment 39. The method of any one of embodiments 24-36, wherein evaluating the degradation of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with an amount of the target in a second cell or second cell lysate lacking the E3 ligase.

[0128] Embodiment 40. The method of any one of embodiments 24-36, wherein evaluating the degradation of the target by the E3-ligase-binding target protein comprises: comparing a level of activity of the target in the cell or cell lysate with the E3-ligase-binding target protein with a level of activity of the target in a cell or cell lysate without the E3-ligase- binding target protein.

[0129] Embodiment 41. The method of any one of embodiments 24-40, wherein the E3 ligase is Von Hippel-Lindau (VHL) E3 ligase.

[0130] Embodiment 42. The method of any one of embodiments 24-40, wherein the E3 ligase is Cereblon.

[0131] Embodiment 43. A method of evaluating the degradation of a target in a cell or cell lysate by a targeting degrader protein, comprising: replacing a genetically encoded amino acid of a degrader protein with a non-genetically- encoded amino acid; reacting the non-genetically-encoded amino acid with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the degrader protein to the precursor to a specificity-directing agent to form a targeting degrader protein; and evaluating the degradation of the target by the targeting degrader protein.

[0132] Embodiment 44. The method of embodiment 43, wherein the degrader protein is anE3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein.

[0133] Embodiment 45. The method of embodiment 43 or 44, wherein the targeting degrader protein binds to the target.

[0134] Embodiment 46. The method of embodiment 43 or embodiment 44, wherein the degrader protein does not bind to the target.

[0135] Embodiment 47. The method of any one of embodiments 43-46, wherein the targeting degrader protein binds to the target at least 10 times more strongly than the degrader protein binds to the target.

[0136] Embodiment 48. The method of any one of embodiments 43-47, wherein the target is a protein.

[0137] Embodiment 49. The method of any one of embodiments 43-47, wherein the target is a protein aggregate.

[0138] Embodiment 50. The method of any one of embodiments 43-47, wherein the target comprises a protein complex comprising the target protein.

[0139] Embodiment 51. The method of any one of embodiments 43-50, wherein the non- genetically-encoded amino acid comprises a tetrazine moiety.

[0140] Embodiment 52. The method of embodiment 51, wherein the non-genetically- encoded amino acid is selected from (S)-2-amino-3-(3-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6- methyl- 1 ,2,4,5-tetrazin-3-yl)phenyl)propanoic acid.

[0141] Embodiment 53. The method of any one of embodiments 43-50, wherein the non- genetically-encoded amino acid comprises a trans-cyclooctene moiety.

[0142] Embodiment 54. The method of any one of embodiments 43-53, wherein the precursor to a specificity-directing agent comprises: a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

[0143] Embodiment 55. The method of any one of embodiments 43-54, wherein the target is a protein susceptible to aggregation.

[0144] Embodiment 56. The method of any one of embodiments 43-54, wherein the target is Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

[0145] Embodiment 57. The method of any one of embodiments 43-54, wherein the target is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

[0146] Embodiment 58. The method of any one of embodiments 43-57, wherein evaluating the degradation of the target by the targeting degrader protein comprises: comparing an amount of the target in the cell or cell lysate with the targeting degrader protein with an amount of the target in a cell or cell lysate without the targeting degrader protein.

[0147] Embodiment 59. The method of any one of embodiments 43-57, wherein evaluating the degradation of the target by the targeting degrader protein comprises: comparing a level of activity of the target in the cell or cell lysate with the targeting degrader protein with a level of activity of the target in a cell or cell lysate without the targeting degrader protein.

[0148] Embodiment 60. A method of evaluating the degradation of a target by a targeting E3 ligase in a cell or cell lysate, comprising: replacing a genetically encoded amino acid of a selected E3 ligase with a non-genetically- encoded amino acid; reacting the non-genetically-encoded amino acid with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the selected E3 ligase to the precursor to a specificity-directing agent to form a targeting E3 ligase; and

[0149] evaluating the degradation of the target by the targeting E3 ligase.

[0150] Embodiment 61. The method of embodiment 60, wherein the targeting E3 ligase binds to the target.

[0151] Embodiment 62. The method of embodiment 60 or embodiment 61, wherein the selected E3 ligase does not bind to the target.

[0152] Embodiment 63. The method of any one of embodiments 60-62, wherein the targeting E3 ligase binds to the target at least 10 times more strongly than the selected E3 ligase binds to the target.

[0153] Embodiment 64. The method of any one of embodiments 60-63, wherein the target is a protein.

[0154] Embodiment 65. The method of any one of embodiments 60-63, wherein the target is a protein aggregate.

[0155] Embodiment 66. The method of any one of embodiments 60-63, wherein the target comprises a protein complex comprising the target protein.

[0156] Embodiment 67. The method of any one of embodiments 60-66, wherein the non- genetically-encoded amino acid comprises a tetrazine moiety.

[0157] Embodiment 68. The method of embodiment 67, wherein the non-genetically- encoded amino acid is selected from (S)-2-amino-3-(3-(6-methyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2- amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6- methyl- 1 ,2,4,5-tetrazin-3-yl)phenyl)propanoic acid.

[0158] Embodiment 69. The method of any one of embodiments 60-66, wherein the non- genetically-encoded amino acid comprises a trans-cyclooctene moiety.

[0159] Embodiment 70. The method of any one of embodiments 60-69, wherein the precursor to a specificity-directing agent comprises: a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

[0160] Embodiment 71. The method of any one of embodiments 60-70, wherein the target is a protein susceptible to aggregation.

[0161] Embodiment 72. The method of any one of embodiments 60-70, wherein the target is Huntingtin aggregate, beta-amyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

[0162] Embodiment 73. The method of any one of embodiments 60-70, wherein the target is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

[0163] Embodiment 74. The method of any one of embodiments 60-73, wherein evaluating the degradation of the target by the targeting E3 ligase comprises: comparing an amount of the target in the cell or cell lysate with the targeting E3 ligase with an amount of the target in a cell or cell lysate without the targeting E3 ligase.

[0164] Embodiment 75. The method of any one of embodiments 60-73, wherein evaluating the degradation of the target by the targeting E3 ligase comprises: comparing a level of activity of the target in the cell or cell lysate with the targeting E3 ligase with a level of activity of the target in a cell or cell lysate without the targeting E3 ligase.

[0165] Embodiment 76. A method of characterizing a candidate site in a candidate protein for PROTAC development, comprising evaluating the interaction of a target with a derivatized candidate protein wherein the candidate protein is derivatized by replacing a genetically-encoded amino acid (GEAA) at the candidate site in the candidate protein with a non-genetically-encoded amino acid (NGAA), and reacting the NGAA with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the candidate protein to the specificity-directing agent to form the derivatized candidate protein; and wherein the evaluation of the interaction of the target with the derivatized candidate protein comprises one or more of: comparing binding of the derivatized candidate protein to the target versus binding of the candidate protein to the target, comparing the amount of the target in the presence of the derivatized candidate protein with the amount of the target in the absence of the derivatized candidate protein, comparing an amount of the target in a first cell or cell lysate with the derivatized candidate protein versus an amount of the target in a second cell or cell lysate without the derivatized candidate protein, comparing a level of activity of the target in a first cell or cell lysate with the derivatized candidate protein versus a level of activity of the target in a second cell or cell lysate without the derivatized candidate protein, comparing stability of the target with the derivatized candidate protein versus stability of the target with the candidate protein,comparing a level of phosphorylation of the target in a first cell or cell lysate with the derivatized candidate protein versus the level of phosphorylation of the target in a second cell or cell lysate without the derivatized candidate protein, or comparing a level of dephosphorylation of the target in a first cell or cell lysate with the derivatized candidate protein versus the level of dephosphorylation of the target in a second cell or cell lysate without the derivatized candidate protein.

[0166] Embodiment 77. The method of embodiment 76, wherein the evaluating comprises comparing the amount of the target in the presence of the derivatized candidate protein with the amount of the target in the absence of the derivatized candidate protein.EXAMPLESExample 1Replacement of Genetically-Encoded. Amino Acid ( GEAA ) with Non-Genetically-Encoded Amino Acid (NGAA)

[0167] A plasmid is designed that contains an amber codon at position 77 of von Hippel- Lindau protein (VHL), as well as a separate plasmid that contains a tRNA synthetase optimized for the non-genetically-encoded amino acid (NGAA) of choice. (See Jang et al., J. Am. Chem. Soc. 2020 April 22; 142(16): 7245-7249.) The amber encoded amino acid sequence of VHL is as follows, where the ‘B’ (marked by a single asterisk) indicates an amber codon at position 77, and a V5 tag (marked by 14 consecutive asterisks) is added at the end of VHL to monitor the levels of the NGAA version of VHL distinct from endogenous VHL:

[0168] Insert ‘B’ for Tet-v3.0Bu (see Jang et al., J. Am. Chem. Soc. 2020 April 22; 142(16): 7245-7249; Tet-v3.0Bu designates (S)-2-amino-3-(3-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid) using an Amber Codon B and adding V5 tag GKPIPNPLLGLDST (SEQ ID NO: ): the amber codon triplet in DNA is (TAG), in mRNA is (UAG), and the corresponding tRNA anticodon is (CUA).

[0169] >sp|P40337|VHL_HUMAN von Hippel-Lindau disease tumor suppressorOS=Homo sapiens OX=9606 GN=VHL PE=1 SV=2 (SEQ ID NO: )MP RRAENWD E AE VGAE E AGVE EYGPEEDGGEES GAE ESGPEESGPEEL GAE E EME AGRP RPVLRSVNSREPSQVIFBNRSPRWLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFR ★DAGTHDGLLVNQTELFVPSLNVDGQP IFANITLPVYTLKERCLQWRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGDGKPIPNPLLGLDST ★★★★★★★★★★★★★★

[0170] The corresponding DNA sequence is as follows (the amber codon is marked by three consecutive asterisks; the V5 tag is marked by 42 consecutive asterisks):

[0171] >EMBOSS_001 (SEQ ID NO: )ATGCCCAGGAGGGCCGAGAACTGGGACGAGGCCGAGGTGGGCGCCGAGGAGGCCGGCGTGGAGGAGTACGGCCCCGAGGAGGACGGCGGCGAGGAGAGCGGCGCCGAGGAGAGCGGCCCCGAGGAGAGCGGCCCCGAGGAGCTGGGCGCCGAGGAGGAGATGGAGGCCGGCAGGCCCAGGCCCGTGCTGAGGAGCGTGAACAGCAGGGAGCCCAGCCAGGTGATCTTCTAGAACAGGAGC★ ★ ★CCCAGGGTGGTGCTGCCCGTGTGGCTGAACTTCGACGGCGAGCCCCAGCCCTACCCCACCCTGCCCCCCGGCACCGGCAGGAGGATCCACAGCTACAGGGGCCACCTGTGGCTGTTCAGGGACGCCGGCACCCACGACGGCCTGCTGGTGAACCAGACCGAGCTGTTCGTGCCCAGCCTGAACGTGGACGGCCAGCCCATCTTCGCCAACATCACCCTGCCCGTGTACACCCTGAAGGAGAGGTGCCTGCAGGTGGTGAGGAGCCTGGTGAAGCCCGAGAACTACAGGAGGCTGGACATCGTGAGGAGCCTGTACGAGGACCTGGAGGACCACCCCAACGTGCAGAAGGACCTGGAGAGGCTGACCCAGGAGAGGATCGCCCACCAGAGGATGGGCGACGGCAAGCCCATCCCCAACCCC★★★★★★★★★★★★★★★★★★★★★CTGCTGGGCCTGGACAGCACC★★★★★★★★★★★★★★★★★★★★★

[0172] These plasmids are inserted into cells amenable to transfections, such as HEK293 cells. The cells are grown in media supplanted with the desired NGAA, such as a tetrazinecontaining NGAA such as Tet-v3.0Bu ((S)-2-amino-3-(3-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid). Confirmation of expression of the VHL with the inserted NGAA is performed using a western blot of the V5 tag.Example 2Preparation of Precursors to Specificity-Directing Agent

[0173] A JQ1 molecule attached to trans-cyclooctene (TCO) is added to cells to perform in-cell click chemistry on a protein with a tetrazine-containing non-genetically-encoded amino acid. JQ1 has the following structure:and can be readily derivatized via its ester group to form part of a larger molecule, such as a specificity-directing agent.

[0174] Trans-cyclooctene has the following structure:grate the trans-cyclooctene-bearing moiety into a larger molecule, such as a specificity-directing agent.

[0175] Exemplary specificity-directing agents include the following:Synthesis of (-)-JQl-PEG-TCOGeneral procedure for preparation of Compound 2 A

[0176] To a mixture of Compound 1A (20 g, 184.88 mmol, 22.70 mL, 1 eq) and Compound IB (3.16 g, 27.73 mmol, 2.90 mL, 0.15 eq) was added Rh2(OAc)4 (204.28 mg, 924.38 umol, 0.005 eq) dropwise under N2 atmosphere via syringe pump over 5 h at 0 °C. The mixture was stirred at 25 °C for 17 h under N2 atmosphere. TLC indicated Compound 1A wasconsumed, and two major new spots with larger polarity was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=l / O to 1 / 1 , Petroleum ether : Ethyl acetate=10:l , Plate 1=0.64,0.58). Compound 2A was obtained as a green oil.

[0177] 1H NMR CDC13 400MHz: 5 ppm = 5.53-5.67 (m, 2H), 4.05-4.11 (m, 2H), 2.48 (ddt, 3.8 Hz, 1H), 2.28 (ddd, 1H), 2.12-2.23 (m, 2H), 2.03-2.11 (m, 2H), 1.75-1.87 (m, 1H), 1.33-1.58 (m, 3H), 1.22-1.26 ppm (m, 3H)General procedure for preparation of Compound 3 A2A 3A

[0178] To a solution of Compound 2A (5 g, 25.74 mmol, 1 eq) in THF (100 mL) was added LAH (2.54 g, 66.92 mmol, 2.6 eq) at 0 °C. The mixture was stirred at 25 °C for 2 hr. TLC indicated no Compound 2A remained, and one major new spot with larger polarity was detected. The reaction mixture was quenched by addition H2O 3 mL at 0 °C, then diluted with aq. 15% NaOH 3 mL and then diluted with H2O 9 mL and extracted with EtOAc 20 mL. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 3A (3.7 g, crude) was obtained as a colourless oil.

[0179] 1H NMR DMSO- d6 400MHz

[0180] 5 ppm = 5.52-5.64 (m, 2H), 3.45 (dd, J = 7.0, 3.6 Hz, 1H), 3.22-3.28 (m, 1H), 2.20- 2.33 (m, 2H), 1.95-2.14 (m, 4H), 1.80-1.93 (m, 1H), 1.49-1.61 (m, 1H), 1.28-1.41 (m, 1H), 0.77-0.90 (m, 1H), 0.60-0.72 (m, 1H), 0.43-0.53 ppm (m, 1H)General procedure for preparation of Compound 4 Asilica gel, AgNO3, Et2O, hexane Flow reactor, UV-irradiation,25 °C, 72 h3A4A

[0181] 10 g silica gel was suspended in HC1 (12 M, 1.64 mL, 1 eq) and then washed the silical gel with water until the pH= 7. After that, the silica gel was filtered and AgNO3 (18.14 g, 106.81 mmol, 5.42 eq) was added.

[0182] Compound 3A (3 g, 19.71 mmol, 1 eq) and methyl benzoate (5.37 g, 39.41 mmol, 4.92 mL, 2 eq) were dissolved in 1000 mL of 1:1 etherhexanes in a quartz flask that was equipped with a magnetic stir bar. The quartz flask was placed in a reactor and connected via PTFE tubing to a custom made column (Flash Silica ,40-60pm,60A,120g, Agela-CS 140120- 0D, Rapid silica gel column) and FMI pump. The bottom of the column was packed with dry silica gel (20 cm), and the top of the column was packed with silver nitrate impregnated silica (9.1 g). The column was flushed with a solution of 1:1 ether:hexanes. The pump was turned on and the rate of circulation was adjusted to about 100 mL per minute and simultaneously degassed with nitrogen for 15 minutes. The lamp (254 nm, 28W) was then turned on, and photolysis was carried out for 72 hours at 25 °C. Then the column was washed with additional solvent (150 mL, hexanes) and then dried by a stream of compressed air. The column was emptied into a flask (1 L), and the silica gel was stirred with ammonium hydroxide (500 mL) and methylene chloride (500 mL) for 5 mins. The silica gel was filtered, and the filter cake was washed with additional methylene chloride (100 mL) and ammonium hydroxide (100 mL). The filtrate was transferred to a separatory funnel. The organic layer was separated, and the ammonium hydroxide layer was washed with methylene chloride (200 mL * 2). The organic layers were combined, washed with 200 mL of water, dried over MgSO4, filtered and concentrated to provide the title product. Compound 4A (0.8 g, crude) was obtained as a yellow oil.

[0183] 1H NMR DMSO- d6 400MHz

[0184] 5 ppm = 5.71-5.88 (m, 1H), 4.99-5.19 (m, 1H), 3.28 (s, 2H), 1.99-2.33 (m, 5H), 1.77-1.91 (m, 2H), 0.95-1.13 (m, 1H), 0.68-0.88 (m, 1H), 0.35-0.66 (m, 2H), 0.19-0.31 ppm (m, 1H)General procedure for preparation of Compound 5 A :4A 5A

[0185] To a solution of Compound 4A (400 mg, 2.63 mmol, 1 eq) and Pyridine (311.76 mg, 3.94 mmol, 318.12 pL, 1.5 eq) in DCM (5 mL) was added Compound 4B (582.58 mg, 2.89 mmol, 1.1 eq) at 20 °C. The mixture was stirred at 20 °C for 1.5 hr. TLC indicated Compound 4A was consumed completely and one main new spot formed. The reaction mixture was concentrated with nitrogen to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=l / O to 5 / 1). Compound 5A (400 mg, crude) was obtained as a yellow solid.

[0186] 1H NMR CDC13 400MHz

[0187] 5 ppm = 8.25-8.32 (m, 2H), 7.35-7.43 (m, 2H), 5.81-5.97 (m, 1H), 5.08-5.27 (m, 1H), 4.07-4.23 (m, 2H), 2.15-2.46 (m, 4H), 1.89-2.02 (m, 2H), 1.00-1.14 (m, 1H), 0.83-0.97 (m, 1H), 0.73-0.82 (m, 1H), 0.50-0.72 ppm (m, 2H)General procedure for preparation of Compound 2 :

[0188] To a solution of Compound 1 (1.8 g, 3.94 mmol, 1 eq) in DCM (18 mL) was added TFA (13.82 g, 121.16 mmol, 9.00 mL, 30.76 eq). The mixture was stirred at 20 °C for 12 hours. LC-MS showed Compound 1 was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. Compound 2 (1.58 g, crude) was obtained as a yellow oil.

[0189] MS-ESI (m / z) calcd for C19H17C1N4O2S [M+l]+: 401.0.General procedure for preparation of Compound 3 :

[0190] To a solution of Compound 2 (1.43 g, 3.57 mmol, 1 eq) and Compound 2X (885.79 mg, 3.57 mmol, 1 eq) in DCM (15 mL) was added DIEA (2.77 g, 21.40 mmol, 3.73 mL, 6 eq) and HATU (1.63 g, 4.28 mmol, 1.2 eq). The mixture was stirred at 20 °C for 12 hours. LC-MS showed Compound 2 was consumed completely and one main peak with desired mass was detected. The reaction mixture was quenched by addition H2O 20 mL and extracted with DCM 60 mL (20 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. Compound 3 (2.2 g, crude) was obtained as a yellow oil.

[0191] MS-ESI (m / z) calcd for C30H39C1N6O5S [M+l]+: 631.2.General procedure for preparation of Compound 4:

[0192] To a solution of Compound 3 (2.2 g, 3.49 mmol, 1 eq) in DCM (20 mL) was added TFA (15.35 g, 134.62 mmol, 10 mL, 38.62 eq). The mixture was stirred at 20 °C for 1 hours LC-MS showed Compound 3 was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. Compound 4 (2 g, crude, FA) was obtained as a yellow oil.

[0193] MS-ESI (m / z) calcd for C25H31C1N6O3S [M+l]+: 531.2.General procedure for preparation of Compound 5

[0194] To a solution of Compound 4 (2 g, 3.47 mmol, 1 eq, FA) in DCM (20 mL) was added DIEA (2.69 g, 20.79 mmol, 3.62 mL, 6 eq), Compound 4X (1.60 g, 6.93 mmol, 2 eq) and HATU (1.58 g, 4.16 mmol, 1.2 eq). The mixture was stirred at 20 °C for 12 hours. LC- MS showed no Compound 4 remained. Several new peaks were shown on LC-MS and desired mass was detected. The reaction mixture was quenched by addition H2O 20 mL and extracted with DCM 60 mL (20 mL * 3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, DCM: MeOH =1 / 0 to 1 / 1), Rf=0.44.Compound 5 (2.5 g, crude) was obtained as a yellow oil.

[0195] 1H NMR CDC13 400MHz

[0196] 5 ppm = 10.92 (br s, 7H), 7.36-7.46 (m, 2H), 7.29-7.35 (m, 2H), 3.67 (dtd, 15H), 3.45-3.61 (m, 10H), 3.43 (s, 3H), 3.09 (qd, J = 7.4, 4.2 Hz, 15H), 2.64 (s, 3H), 2.38 (s, 3H), 1.35 ppm (s, 20H)

[0197] The residue was purified by prep-HPLC (LA condition), column: Phenomenex Luna C18 200*40mm*10um; mobile phase: [H2O (0.2%EA) - ACN]; gradient : 35%-65% B over 8.0 min. Compound 5 (110 mg, crude) was obtained as a white solid.

[0198] MS-ESI (m / z) calcd for C36H50C1N7O6S [M+l]+: 744.3General Procedure for Preparation of Compound 6

[0199] To a solution of Compound 5 (60 mg, 80.61 pmol, 1 eq) in DCM (2 mL) was added TFA (614.00 mg, 5.38 mmol, 400.00 pL, 66.80 eq). The mixture was stirred at 20 °C for 2 hours. LC-MS showed Compound 5 was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. Compound 6 (60 mg, crude, TFA) was obtained as a yellow oil.

[0200] MS-ESI (m / z) calcd for C31H42C1N7O4S [M+l]+: 644.3General procedure for preparation of Compound (-)-JQl-PEG-TCO

[0201] To a solution of Compound 5A (60 mg, 79.13 pmol, 1 eq, TFA) in DCM (2 mL) was added was added DIEA (61.36 mg, 474.78 pmol, 82.70 pL, 6 eq) and Compound 6 (27.62 mg, 87.04 pmol, 1.1 eq). The mixture was stirred at 20 °C for 2.5 hours. LC-MS showed Compound 6 was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under N2 to give a residue. The residue was purified by prep-HPLC (basic condition: column: Phenomenex Gemini NX- C18(75*30mm*3um);mobile phase: [H20(0.05% NH3H2O+10mM NH4HCO3)-ACN]; gradient:40%-70% B over 8.0 min). (-)-JQl-PEG-TCO (28.2 mg, 34.29 pmol, 43.33% yield, 100% purity) was obtained as a white solid.

[0202] 1H NMR DMSO-d6 400MHz

[0203] 5 ppm = 8.28 (t, J = 5.6 Hz, 1H), 7.82 (br t, J = 5.8 Hz, 1H), 7.36-7.54 (m, 4H), 6.94-7.10 (m, 1H), 5.68-5.81 (m, 1H), 4.99-5.21 (m, 1H), 4.50 (t, J = 8.0 Hz, 1H), 3.73-3.95 (m, 2H), 3.53 (br s, 4H), 3.43-3.47 (m, 2H), 3.39 (t, J = 6.0 Hz, 2H), 3.21-3.28 (m, 3H), 3.18 (q, J = 4.8 Hz, 2H), 2.91 (q, J = 6.8 Hz, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 2.22-2.29 (m, 1H), 2.16 (td, J = 8.2, 3.6 Hz, 2H), 2.03 (br t, 2H), 1.84 (td, 2H), 1.62 (s, 3H), 1.45 (quin, 2H), 1.30-1.39 (m, 2H), 1.13-1.24 (m, 3H), 0.92-1.10 (m, 1H), 0.63-0.89 (m, 2H), 0.44-0.61 (m, 2H), 0.30-0.41 ppm (m, 1H)

[0204] LCMS (ESI+): m / z 822.1 (M+H)+Synthesis of (+)-JQl-PEG-TCO

[0205] (+)-JQl-PEG-TCO is synthesized as follows:(+)-JQ1-PEG-TCOGeneral procedure for preparation of Compound 2R

[0206] To a solution of Compound 1R (1.5 g, 3.28 mmol, 1 eq) in DCM (15 mL) was added TFA (374.27 mg, 3.28 mmol, 243.03 uL, 1 eq) at 0 °C. The mixture was stirred at 25 °C for 2 hr. Several new peaks were shown on LC-MS desired compound was detected. The combined organic layers were concentrated under reduced pressure to give a residue.Compound 2R (2 g, crude, TFA) was obtained as a yellow oil.

[0207] MS-ESI (m / z) calcd for C19H17C1N4O2S [M+H]+: 401.0 / 403.0.General procedure for preparation of Compound 3R:

[0208] To a solution of Compound 2R (1.9 g, 4.74 mmol, 1 eq) and Compound 2A (1.18 g, 4.74 mmol, 1 eq) in DMF (20 mL) was added HATU (2.70 g, 7.11 mmol, 1.5 eq) and DIEA (1.84 g, 14.22 mmol, 2.48 mL, 3 eq). The mixture was stirred at 40 °C for 12 hr. Several new peaks were shown on LC-MS as desired compound 3R was detected. The reaction mixture was diluted with H2O 20 mL and extracted with EtOAc 60 mL (20 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Dichloromethane: Methanol= 100 / 1 to 10 / 1, Dichloromethane: Methanol=10:l, Plate 1=0.52). Compound 3R (2.61 g, 4.14 mmol, 87.25% yield) was obtained as a yellow gum. HNMR (Cpd.3), LCMS(Cpd.3)

[0209] MS-ESI (m / z) calcd for C30H39C1N6O5S [M+H]+: 631.2

[0210] 1H NMR DMSO-d6 400MHz

[0211] 5 (ppm) = 7.41 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 4.648 (t, J = 8.4 Hz, 1H), 4.107 (, J = 7.2 Hz, 1H), 3.706 - 3.716 (m, 3H), 3.609-3.636 (m, 4H), 3.515-3.589 (s, 2H), 3.338-3.487 (m, 2H), 2.965 (s, 1H), 2.887 (s, 1H), 2.407 (s, 3H), 1.509 (s, 3H), 1.411 - 1.492 (m, 9H)General procedure for preparation of Compound 4R:

[0212] To a solution of Compound 3R (1.6 g, 2.53 mmol, 1 eq) in DCM (20 mL) was added TFA (4.93 g, 43.22 mmol, 3.2 mL, 17.05 eq). The mixture was stirred at 25 °C for 1 hr. LC-MS showed Compound 3R was consumed completely and one main peak with desired m / z was detected. The reaction mixture was concentrated under reduced pressure to give a residue. Compound 4R (1.35 g, crude) was obtained as a colorless oil.

[0213] MS-ESI (m / z) calcd for C25H31C1N6O3S [M+H]+: 531.2

[0214] To a solution of Compound 4R (500 mg, 941.50 umol, 1 eq) and Compound 5A (298.77 mg, 941.50 umol, 1 eq) in DCM (5 mL) was added DIEA (365.05 mg, 2.82 mmol, 491.98 uL, 3 eq). The mixture was stirred at 25 °C for 14 hr. LC-MS showed that the desired mass of the product was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (basic condition, column: Waters Xbridge Prep OBD C18 150*40mm*10um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; B%: 50%-80%, 8min). Compound (+)-JQl-PEG-TCO (80.7 mg, 108.37 umol, 11.51% yield, 95.25% purity) was obtained as a white solid.

[0215] Spectrum: 1H NMR DMSO-d6 400MHz: 5 (ppm) = 8.27 (br t, 1H), 7.51 - 7.46 (m, 2H), 7.45 - 7.38 (m, 2H), 7.21 - 6.95 (m, 1H), 5.84 - 5.69 (m, 1H), 5.19 - 5.00 (m, 1H), 4.50 (dd, 1H), 3.95 - 3.75 (m, 2H), 3.52 (s, 4H), 3.47 - 3.42 (m, 2H), 3.40 (br t, J = 5.8 Hz, 2H), 3.29 - 3.17 (m, 5H), 3.11 (q, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 2.35 - 1.95 (m, 5H), 1.90 - 1.76 (m, 2H), 1.27 - 0.95 (m, 2H), 0.89 - 0.63 (m, 2H), 0.61 - 0.36 (m, 2H)

[0216] LCMS (ESI+): m / z 709.3 (M+H)+Synthesis of JQ1 -propylene-TCO

[0217] JQl-propylene-TCO:is readily prepared by reacting [(4E)-cyclooct-4-en-l-yl] N-(3-aminopropyl)carbamate (Aldrich catalog # 790451):in the presence of suitable coupling reagents to form the amide linkage, such as HATU and DIEA or dicyclopropylcarbodiimide and DIEA, in a suitable solvent such as DMF or CH2CI2.Example 3Reaction of Non-Genetically-Encoded Amino Acid (NGAA) With a Precursor to a Specificity- Directing Agent

[0218] A VHL protein with the inserted NGAA is prepared as described in Example 1. The VHL protein is reacted with the JQl-propylene-TCO specificity-directing agent, forming a VHL protein bearing a JQ1 moiety, designated VHL-propylene-JQl.Example 4Evaluation of Von Hippel-Lindau VEIL) Protein Modified with Specificity-Directing Agent

[0219] The resulting effects on cells, cell lysates, or other biological compositions by a protein modified with a specificity-directing agent, as described in Examples 1 and 2, are evaluated.

[0220] A VHL-propylene-JQl is prepared as described in Examples 1, 2, and 3. The levels of BRD4 are monitored using Western blotting as a function of both dose and duration of treatment of cells (grown with NGAA in the media) with the JQl-propylene-TCO specificitydirecting agent. Loss of BRD4 signal demonstrates that functional complexes between VHL and BRD4 have been achieved. Proper controls including proteasome inhibition, JQ1 competition, and measuring BRD4 levels in cells not containing NGAA-inserted VHL that are treated with JQ1 -propylene TCO, can be used to demonstrate the specificity of the reaction, that is, that BRD4 is specifically degraded by the VHL-propylene-JQl.Example 5Formation of an E3 -Ligase-Binding Target Protein: Degradation of Green Fluorescent Protein (GFP) Modified with an E3 -Ligase-Binding Agent

[0221] HEK293T cells were transfected with a tetrazine amino acid recognizing t-RNA synthetase and GEP with an amber codon (TAG) inserted at amino acid 150, which is normally asparagine, in the presence of tetrazine amino acid (Tet-v3.0Bu, synthesized as described in J. Am. Chem. Soc. 2020, 142(16):7245-7249 (2020 DOI:10.1021 / jacs.9bl 1520) overnight. The next day, the cells were washed to remove any free tetrazine amino acid and then treated with either DMSO, 500 nM of sTCO (Compound 4A in Example 2, which reacts with tetrazine but is otherwise non-functional) 500 nM of CC-220 linked to TCO (CC-220 is also known as Iberdomide (CAS Registry No. 1323403-33-3), a CRBN E3-ligase recruiter, and is commercially available from various suppliers, e.g. Sigma- Aldrich), or excess (10 pM) of free CC-220 and 500 nM of TCO-linked CC-220. All treatments were performed for 6hr. A protocol for linkage of CC-220 to TCO is shown below.

[0222] The results are shown in FIG. 4. The leftmost bar shows the amount of GFP in control cells. Ligation of tetrazine amino acid 150 with sTCO does not reduce GFP levels, as shown in the second bar from the left. 500 nM of TCO-linked CC-220 significantly (p < 0.0001) reduces GFP, as shown in the third bar from the left. This reduction is rescued by an excess of the CRBN binding compound CC-220, as shown in the rightmost bar, showing the degradation is CRBN dependent. The bars represent DMSO-normalized GFP intensity, depicting the mean ± the standard error of the mean.

[0223] These results show that a target protein (GFP) in a cell, in which a non-genetically- encoded amino acid (a tetrazine amino acid) has been inserted, can react with an E3-ligase- binding agent (TCO-linked CC-220), and the resulting E3 -ligase-binding target protein recruits E3 ligase, resulting in degradation of the target protein.Protocol for Linkage of CC-220 to TCO

[0224] CC-220 (iberdomide) is coupled to sTCO using N-Boc-3,6-dioxa-l,8-octanediamine according to the following procedures.General procedure for preparation of Compound 8:

[0225] To a solution of Compound 7 (500 mg, 1.81 mmol, 1 eq in DMF (10 mL) were added Compound 7x (449.49 mg, 1.81 mmol, 1 eq) and DIEA (467.90 mg, 3.62 mmol, 630.59 pL, 2 eq). The mixture was stirred at 90 °C for 12 hours. LC-MS showed little Compound 7 remained and one main peak with desired mass was detected. The reaction mixture was diluted with H2O (2 mL) and extracted with EtOAc (2 mL * 3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Petroleum ether / Ethyl acetate = 1 / 0 to 1 / 3). Compound 8 (400 mg, crude) was obtained as a white solid.

[0226] MS-ESI (m / z) calcd for C24H32N4O8 [M+l]+: 505.5.

[0227] 'H NMR DMSO-tfc 400MHz: 5 ppm = 11.10 (s, 1H), 7.56-7.60 (t, J = 7.6 Hz, 1H), 7.14-1.16 (d, J= 8.4 Hz, 1H), 7.03-7.05 (d, J = 6.8 Hz, 1H), 6.74-6.76 (m, 1H), 6.60-6.62 (t, J = 5.6 Hz, 2H), 5.03-5.08 (m, 1H), 3.56-3.61 (m, 2H), 3.51-3.55 (m, 2H), 3.47-3.50 (m, 4H), 3.33-3.37 (m, 2H), 3.04-3.06 (m, 2H), 2.29 (m, 1H), 2.50-2.56 (m, 2H), 2.01-2.04 (m, 1H), 1.36 (s, 9H)General procedure for preparation of Compound 9:8 9

[0228] To a solution of Compound 8 (150 mg, 297.31 pmol, 1 eq) in DCM (2 mL) was added TFA (1.54 g, 13.46 mmol, 1 mL, 45.28 eq). The mixture was stirred at 20 °C for 2 hours. LC-MS showed Compound 8 was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to crude Compound 9 (130 mg, crude) as a yellow oil.

[0229] MS-ESI (m / z) calcd for C19H24N4O6 [M+l]+: 405.4.General procedure for preparation of TCO-linked CC-220:TCO-linked- CC-220

[0230] To a solution of Compound 9 (65 mg, 160.73 pmol, 1 eq) in DCM (1.5 mL) were added DIEA (124.64 mg, 964.35 pmol, 167.97 pL, 6 eq) and Compound 5A (61.20 mg, 192.87 pmol, 1.2 eq). The mixture was stirred at 20 °C for 1 hour. LC-MS showed Compound 5 was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under N2 to give a residue. The residue was purified by prep-HPLC (basic condition: column: Waters Xbridge Prep OBD Cis 150*40mm*10um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; gradient: 45%-75% B over 8 min). TCO-linked CC-220 (14.1 mg, 23.73 pmol, 14.76% yield, 98.04% purity) was obtained as a yellow solid.

[0231] Spectrum: 'H NMR DMSO-rfe 400MHz 5 ppm = 7.58 (t, J= 7.6 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.99-7.07 (m, 1H), 6.61 (br t, J = 5.6 Hz, 1H), 5.70-5.82 (m, 1H), 5.54-5.69 (m, 1H), 5.49-5.85 (m, 1H), 5.05 (br dd, J = 13.2, 5.4 Hz, 1H), 3.79 (br dd, J = 10.8, 6.8 Hz, 1H), 3.58-3.65 (m, 2H), 3.44-3.58 (m, 5H), 3.37-3.42 (m, 2H), 3.10 (br t, J= 5.6 Hz, 2H), 2.76-2.97 (m, 1H), 2.52-2.71 (m, 3H), 1.80-2.41 (m, 6H), 1.60-1.77 (m, 1H), 0.98-1.39 (m, 2H), 0.70-0.92 (m, 1H), 0.41-0.66 ppm (m, 1H)

[0232] LCMS (ESI+): m / z 583.3 (M+H)

[0233] It is understood that the present disclosure has been made only by way of example, and that numerous changes in the combination and arrangement of parts can be resorted to by those skilled in the art without departing from the spirit and scope of present disclosure.

[0234] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims

CLAIMSWhat is claimed is:

1. A method of evaluating the interaction of a target with a derivatized protein, comprising: replacing a genetically-encoded amino acid (GEAA) of a first protein with a non- genetically-encoded amino acid (NGAA); reacting the NGAA with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the first protein to the specificity-directing agent to form the derivatized protein; and evaluating the interaction of the derivatized protein with the target.

2. The method of claim 1, wherein the derivatized protein binds to the target.

3. The method of claim 1 or claim 2, wherein the first protein does not bind to the target.

4. The method of claim 1 or claim 2, wherein the derivatized protein binds to the target at least 10 times more strongly than the first protein binds to the target.

5. The method of any one of claims 1-4, wherein the target comprises a second protein.

6. The method of any one of claims 1-4, wherein the target comprises a protein complex.

7. The method of any one of claims 1-4, wherein the target comprises a protein aggregate.

8. The method of any one of claims 1-7, wherein the non-genetically-encoded amino acid comprises a tetrazine moiety.

9. The method of claim 8, wherein the non-genetically-encoded amino acid is (S)-2-amino-3- (3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-ethyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3- (6-methyl-l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-phenyl- 1,2,4, 5-tetrazin-3- yl)propanoic acid, (S)-2-amino-3-(6-(pyridin-2-yl)-l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6- isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3-(4-(6-butyl-l,2,4,5- tetrazin- 3 -y l)pheny l)prop anoic acid.

10. The method of any one of claims 1-7, wherein the non-genetically-encoded amino acid comprises a trans-cyclooctene moiety11. The method of any one of claims 1-10, wherein the precursor to a specificity-directing agent comprises: a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

12. The method of any one of claims 1-11, wherein evaluating the interaction of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with the derivatized protein with an amount of the target in a cell or cell lysate without the derivatized protein.

13. The method of any one of claims 1-11, wherein evaluating the interaction of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate where the precursor to a specificity-directing agent was added with an amount of the target in a second cell or second cell lysate where the precursor to a specificity-directing agent was not added.

14. The method of any one of claims 1-11, wherein evaluating the interaction of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with an amount of the target in a second cell or second cell lysate lacking the first protein.

15. The method of any one of claims 1-11, wherein evaluating the interaction of the target by the derivatized protein comprises: comparing a level of activity of the target in the cell or cell lysate with the target with a level of activity of the target in a cell or cell lysate without the target.

16. The method of any one of claims 1-15, wherein the first protein is a protein that induces degradation of the target.

17. The method of claim 16, wherein the first protein is an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein.

18. The method of any one of claims 1-17, wherein the target is a protein susceptible to aggregation.

19. The method of any one of claims 1-17, wherein the target is Huntingtin aggregate, betaamyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

20. The method of any one of claims 1-15, wherein the first protein is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

21. The method of any one of claims 1-15 or 20, wherein the target is a protein that induces degradation of the derivatized protein.

22. The method of claim 21, wherein the target is an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein.

23. The method of claim 21, wherein the target is Von Hippel-Lindau (VHL) E3 ligase or Cereblon.

24. A method of evaluating the degradation of a target by an E3 ligase in a cell or cell lysate, comprising: replacing an amino acid of a target protein with a non-genetically-encoded amino acid (NGAA); reacting the non-genetically-encoded amino acid with a precursor to an E3-ligase- binding agent, wherein the reacting results in covalent binding of the target protein to the E3-ligase binding agent to form an E3-ligase-binding target protein; and evaluating the degradation of the target in the cell or cell lysate.

25. The method of claim 24, wherein the amino acid of the target protein is a cysteine, lysine, serine, threonine, histidine, tyrosine, glutamic acid, or aspartic acid residue.

26. The method of claim 24 or claim 25, wherein the E3-ligase-binding target protein binds to an E3 ligase in the cell or cell lysate.

27. The method of any one of claims 24-26, wherein the target comprises the target protein.

28. The method of any one of claims 24-26, wherein the target comprises a protein complex comprising the target protein.

29. The method of any one of claims 24-26, wherein the target comprises an aggregate of the target protein.

30. The method of any one of claims 24-29, wherein the non-genetically-encoded amino acid comprises a tetrazine moiety.

31. The method of claim 30, wherein the non-genetically-encoded amino acid is (S)-2- amino-3-(3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6- ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-l,2,4,5- tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(6-methyl-l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-phenyl- l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-(pyridin-2-yl)- 1,2,4, 5-tetrazin-3- yl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3- (4-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid.

32. The method of any one of claims 24-29, wherein the non-genetically-encoded amino acid comprises a trans-cyclooctene moiety.

33. The method of any one of claims 24-32, wherein the precursor to an E3-ligase-binding agent comprises:a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to an E3 ligase.

34. The method of any one of claims 24-33, wherein the target is a protein susceptible to aggregation.

35. The method of any one of claims 24-33, wherein the target is Huntingtin aggregate, betaamyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

36. The method of any one of claims 24-33, wherein the target protein is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

37. The method of any one of claims 24-36, wherein evaluating the degradation of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with the E3-ligase-binding target protein with an amount of the target in a cell or cell lysate without the E3-ligase-binding target protein.

38. The method of any one of claims 24-36, wherein evaluating the degradation of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate where the E3-ligase-binding agent was added with an amount of the target in a second cell or second cell lysate where the E3- ligase-binding agent was not added.

39. The method of any one of claims 24-36, wherein evaluating the degradation of the target in the cell or cell lysate comprises: comparing an amount of the target in the cell or cell lysate with an amount of the target in a second cell or second cell lysate lacking the E3 ligase.

40. The method of any one of claims 24-36, wherein evaluating the degradation of the target by the E3-ligase-binding target protein comprises:comparing a level of activity of the target in the cell or cell lysate with the E3-ligase-binding target protein with a level of activity of the target in a cell or cell lysate without the E3-ligase- binding target protein.

41. The method of any one of claims 24-40, wherein the E3 ligase is Von Hippel-Lindau (VHL) E3 ligase.

42. The method of any one of claims 24-40, wherein the E3 ligase is Cereblon.

43. A method of evaluating the degradation of a target in a cell or cell lysate by a targeting degrader protein, comprising: replacing a genetically encoded amino acid of a degrader protein with a non- genetically-encoded amino acid; reacting the non-genetically-encoded amino acid with a precursor to a specificitydirecting agent, wherein the reacting results in covalent binding of the degrader protein to the precursor to a specificity-directing agent to form a targeting degrader protein; and evaluating the degradation of the target by the targeting degrader protein.

44. The method of claim 43, wherein the degrader protein is an E3 ligase, an E2 ligase, an El ligase, or an autophagy-directing protein.

45. The method of claim 43 or 44, wherein the targeting degrader protein binds to the target.

46. The method of claim 43 or claim 44, wherein the degrader protein does not bind to the target.

47. The method of any one of claims 43-46, wherein the targeting degrader protein binds to the target at least 10 times more strongly than the degrader protein binds to the target.

48. The method of any one of claims 43-47, wherein the target is a protein.

49. The method of any one of claims 43-47, wherein the target is a protein aggregate.

50. The method of any one of claims 43-47, wherein the target comprises a protein complex comprising the target protein.

51. The method of any one of claims 43-50, wherein the non-genetically-encoded amino acid comprises a tetrazine moiety.

52. The method of claim 51, wherein the non-genetically-encoded amino acid is selected from (S)-2-amino-3-(3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3- (3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-1.2.4.5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(6-methyl-l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-phenyl-1.2.4.5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-(pyridin-2-yl)- 1,2,4, 5-tetrazin-3- yl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3- (4-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid.

53. The method of any one of claims 43-50, wherein the non-genetically-encoded amino acid comprises a trans-cyclooctene moiety.

54. The method of any one of claims 43-53, wherein the precursor to a specificity-directing agent comprises: a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

55. The method of any one of claims 43-54, wherein the target is a protein susceptible to aggregation.

56. The method of any one of claims 43-54, wherein the target is Huntingtin aggregate, betaamyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

57. The method of any one of claims 43-54, wherein the target is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

58. The method of any one of claims 43-57, wherein evaluating the degradation of the target by the targeting degrader protein comprises: comparing an amount of the target in the cell or cell lysate with the targeting degrader protein with an amount of the target in a cell or cell lysate without the targeting degrader protein.

59. The method of any one of claims 43-57, wherein evaluating the degradation of the target by the targeting degrader protein comprises: comparing a level of activity of the target in the cell or cell lysate with the targeting degrader protein with a level of activity of the target in a cell or cell lysate without the targeting degrader protein.

60. A method of evaluating the degradation of a target by a targeting E3 ligase in a cell or cell lysate, comprising: replacing a genetically encoded amino acid of a selected E3 ligase with a non- genetically-encoded amino acid; reacting the non-genetically-encoded amino acid with a precursor to a specificitydirecting agent, wherein the reacting results in covalent binding of the selected E3 ligase to the precursor to a specificity-directing agent to form a targeting E3 ligase; and evaluating the degradation of the target by the targeting E3 ligase.

61. The method of claim 60, wherein the targeting E3 ligase binds to the target.

62. The method of claim 60 or claim 61, wherein the selected E3 ligase does not bind to the target.

63. The method of any one of claims 60-62, wherein the targeting E3 ligase binds to the target at least 10 times more strongly than the selected E3 ligase binds to the target.

64. The method of any one of claims 60-63, wherein the target is a protein.

65. The method of any one of claims 60-63, wherein the target is a protein aggregate.

66. The method of any one of claims 60-63, wherein the target comprises a protein complex comprising the target protein.

67. The method of any one of claims 60-66, wherein the non-genetically-encoded amino acid comprises a tetrazine moiety.

68. The method of claim 67, wherein the non-genetically-encoded amino acid is selected from (S)-2-amino-3-(3-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3- (3-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-isopropyl-1.2.4.5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(3-(6-butyl- 1,2,4, 5-tetrazin-3- yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-methyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(6-methyl-l,2,4,5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-phenyl-1.2.4.5-tetrazin-3-yl)propanoic acid, (S)-2-amino-3-(6-(pyridin-2-yl)- 1,2,4, 5-tetrazin-3- yl)propanoic acid, (S)-2-amino-3-(4-(6-ethyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, (S)-2-amino-3-(4-(6-isopropyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid, or (S)-2-amino-3- (4-(6-butyl-l,2,4,5-tetrazin-3-yl)phenyl)propanoic acid.

69. The method of any one of claims 60-66, wherein the non-genetically-encoded amino acid comprises a trans-cyclooctene moiety.

70. The method of any one of claims 60-69, wherein the precursor to a specificity-directing agent comprises: a) a functional group capable of forming a covalent bond with the non-genetically-encoded amino acid, and b) a binding group that binds to the target.

71. The method of any one of claims 60-70, wherein the target is a protein susceptible to aggregation.

72. The method of any one of claims 60-70, wherein the target is Huntingtin aggregate, betaamyloid, a PolyQ protein aggregate, or PrPSc(scrapie isoform of the prion protein).

73. The method of any one of claims 60-70, wherein the target is huntingtin, amyloid precursor protein, a polyQ protein, or PrPc(non- scrapie isoform of the prion protein).

74. The method of any one of claims 60-73, wherein evaluating the degradation of the target by the targeting E3 ligase comprises: comparing an amount of the target in the cell or cell lysate with the targeting E3 ligase with an amount of the target in a cell or cell lysate without the targeting E3 ligase.

75. The method of any one of claims 60-73, wherein evaluating the degradation of the target by the targeting E3 ligase comprises: comparing a level of activity of the target in the cell or cell lysate with the targeting E3 ligase with a level of activity of the target in a cell or cell lysate without the targeting E3 ligase.

76. A method of characterizing a candidate site in a candidate protein for PROTAC development, comprising evaluating the interaction of a target with a derivatized candidate protein wherein the candidate protein is derivatized by replacing a genetically-encoded amino acid (GEAA) at the candidate site in the candidate protein with a non-genetically-encoded amino acid (NGAA), and reacting the NGAA with a precursor to a specificity-directing agent, wherein the reacting results in covalent binding of the candidate protein to the specificity-directing agent to form the derivatized candidate protein; and wherein the evaluation of the interaction of the target with the derivatized candidate protein comprises one or more of: comparing binding of the derivatized candidate protein to the target versus binding of the candidate protein to the target, comparing the amount of the target in the presence of the derivatized candidate protein with the amount of the target in the absence of the derivatized candidate protein, comparing an amount of the target in a first cell or cell lysate with the derivatized candidate protein versus an amount of the target in a second cell or cell lysate without the derivatized candidate protein, comparing a level of activity of the target in a first cell or cell lysate with the derivatized candidate protein versus a level of activity of the target in a second cell or cell lysate without the derivatized candidate protein, comparing stability of the target with the derivatized candidate protein versus stability of the target with the candidate protein,comparing a level of phosphorylation of the target in a first cell or cell lysate with the derivatized candidate protein versus the level of phosphorylation of the target in a second cell or cell lysate without the derivatized candidate protein, or comparing a level of dephosphorylation of the target in a first cell or cell lysate with the derivatized candidate protein versus the level of dephosphorylation of the target in a second cell or cell lysate without the derivatized candidate protein.

77. The method of claim 76, wherein the evaluating comprises comparing the amount of the target in the presence of the derivatized candidate protein with the amount of the target in the absence of the derivatized candidate protein.

Citation Information

Patent Citations

  • Peptide derivative fusion inhibitors of HIV infection

    US20140187476A1

  • Modified Relaxin Polypeptides and Their Uses

    US20220257720A1

  • High-throughput engineering of molecular glues

    WO2023015237A1

Cited By

  • Tetrazine amino acids and methods for their production and use

    WO2025166249A1